Pivotal readout
Novartis's Rhapsido keeps working through one year in chronic inducible urticaria
In the phase 3 RemIND study, remibrutinib responses held to week 52 across three urticaria subtypes: 46.8% in symptomatic dermographism, 83.3% in cold urticaria and 58.2% in cholinergic urticaria. Patients switched to the drug from placebo after 24 weeks improved too. Safety matched earlier experience, and more regulatory filings are planned.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.